id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-3316-0003,FDA,FDA-2015-E-3316,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-02T05:00:00Z,2015,11,2015-11-02T05:00:00Z,,2015-11-02T15:29:52Z,,0,0,0900006481cfe1a8
FDA-2015-E-3316-0002,FDA,FDA-2015-E-3316,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2015-09-10T04:00:00Z,2015,9,2015-09-10T04:00:00Z,,2015-09-10T17:16:30Z,,0,0,0900006481c66014
FDA-2015-E-3316-0001,FDA,FDA-2015-E-3316,"Patent Extension Application from Oblon Spivak, McClelland, Maier & Neustadt, LLP (on behalf of  Ajinomoto Co., Inc.)",Other,Application,2015-09-10T04:00:00Z,2015,9,2015-09-10T04:00:00Z,,2015-09-10T19:18:48Z,,0,0,0900006481c66016